ACUTAAS

Acutaas Chemicals Limited

Specialty and pharmaceutical chemicals manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

acutaas.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹3206.00
Market cap
26,249 Cr
Stock P/E
68.0
P/B
15.88
Dividend yield
0.0%
ROE (FY26)
20.8%
ROCE (FY26)
28.0%
Operating margin (FY26)
33.2%
Debt / equity (FY26)
0.02
OCF / EBITDA (FY26)
60.8%
OCF / EBITDA (3Y)
63.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Acutaas Chemicals makes the advanced chemical building blocks that pharmaceutical companies use to produce their medicines, including contract development and manufacturing (CDMO) work for innovator drug makers.

Company snapshot

23rdBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 26.6% — the business keeps a healthy share of every rupee it earns.
3 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales172 Cr166 Cr225 Cr177 Cr247 Cr275 Cr308 Cr207 Cr306 Cr393 Cr433 Cr330 Cr
Operating expenses (approx.)148 Cr140 Cr182 Cr147 Cr198 Cr206 Cr224 Cr156 Cr211 Cr243 Cr249 Cr217 Cr
EBITDA25 Cr27 Cr43 Cr30 Cr49 Cr69 Cr85 Cr51 Cr95 Cr151 Cr184 Cr113 Cr
OPM %14.4%15.9%19.2%16.7%19.8%25.0%27.5%24.6%31.1%38.3%42.4%34.3%
Other income2 Cr3 Cr1 Cr1 Cr8 Cr2 Cr6 Cr16 Cr10 Cr5 Cr11 Cr2 Cr
Interest0.82 Cr3 Cr2 Cr4 Cr0.50 Cr0.69 Cr0.60 Cr0.64 Cr0.58 Cr0.86 Cr1 Cr1 Cr
Depreciation4 Cr4 Cr5 Cr6 Cr7 Cr6 Cr7 Cr8 Cr8 Cr10 Cr10 Cr10 Cr
Profit before tax-10 Cr24 Cr37 Cr20 Cr50 Cr63 Cr83 Cr58 Cr96 Cr145 Cr184 Cr104 Cr
Tax %-71.2%24.9%31.0%26.4%24.9%28.2%24.3%24.2%25.3%26.6%26.9%27.8%
Net profit-17 Cr18 Cr26 Cr15 Cr38 Cr45 Cr63 Cr44 Cr72 Cr106 Cr134 Cr75 Cr
EPS (₹)₹-4.67₹4.83₹6.86₹3.67₹9.38₹11.35₹7.80₹5.41₹8.82₹13.19₹16.09₹9.07

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales239 Cr240 Cr341 Cr520 Cr617 Cr717 Cr1,007 Cr1,339 CrSign in free for the trailing twelve months
Operating expenses (approx.)196 Cr199 Cr260 Cr415 Cr494 Cr589 Cr775 Cr859 CrSign in free for the trailing twelve months
EBITDA42 Cr41 Cr80 Cr105 Cr123 Cr128 Cr232 Cr480 CrSign in free for the trailing twelve months
OPM %17.6%17.1%23.5%20.2%19.9%17.9%23.0%35.9%Sign in free for the trailing twelve months
Other income0.38 Cr3 Cr1 Cr3 Cr4 Cr7 Cr17 Cr42 CrSign in free for the trailing twelve months
Interest5 Cr6 Cr6 Cr6 Cr2 Cr6 Cr6 Cr3 CrSign in free for the trailing twelve months
Depreciation3 Cr4 Cr4 Cr10 Cr12 Cr16 Cr27 Cr36 CrSign in free for the trailing twelve months
Profit before tax35 Cr35 Cr72 Cr91 Cr112 Cr82 Cr216 Cr483 CrSign in free for the trailing twelve months
Tax %33.7%21.0%24.7%21.3%25.7%40.5%25.8%26.2%Sign in free for the trailing twelve months
Net profit23 Cr27 Cr54 Cr72 Cr83 Cr49 Cr160 Cr356 CrSign in free for the trailing twelve months
EPS (₹)₹7.40₹8.72₹17.14₹21.03₹22.86₹11.67₹19.81₹43.51Sign in free for the trailing twelve months
Dividend payout %———0.0%13.1%22.4%7.7%3.4%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital11 Cr11 Cr32 Cr36 Cr36 Cr37 Cr41 Cr41 Cr
Reserves72 Cr101 Cr135 Cr486 Cr558 Cr637 Cr1,269 Cr1,613 Cr
Borrowings48 Cr54 Cr117 Cr0.84 Cr4 Cr217 Cr8 Cr26 Cr
Other liabilities83 Cr66 Cr129 Cr136 Cr169 Cr196 Cr221 Cr247 Cr
Total liabilities213 Cr232 Cr413 Cr659 Cr767 Cr1,096 Cr1,549 Cr1,984 Cr
Fixed assets (net)58 Cr62 Cr161 Cr158 Cr222 Cr360 Cr505 Cr633 Cr
CWIP2 Cr12 Cr0.20 Cr3 Cr26 Cr125 Cr130 Cr332 Cr
Investments2 Cr2 Cr1 Cr2 Cr2 Cr0.20 Cr0.20 Cr0.20 Cr
Loans & advances———0.65 Cr1 Cr2 Cr2 Cr3 Cr
Inventories39 Cr52 Cr60 Cr112 Cr119 Cr157 Cr180 Cr231 Cr
Trade receivables76 Cr56 Cr121 Cr164 Cr230 Cr206 Cr290 Cr363 Cr
Cash & bank0.49 Cr4 Cr3 Cr10 Cr31 Cr30 Cr185 Cr216 Cr
Other assets37 Cr44 Cr67 Cr209 Cr137 Cr216 Cr256 Cr206 Cr
Total assets213 Cr232 Cr413 Cr659 Cr767 Cr1,096 Cr1,549 Cr1,984 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity15 Cr27 Cr27 Cr-9 Cr66 Cr125 Cr118 Cr292 Cr
Cash from investing-21 Cr-24 Cr-100 Cr-124 Cr-33 Cr-365 Cr-224 Cr-266 Cr
Cash from financing6 Cr0.19 Cr72 Cr140 Cr-12 Cr239 Cr261 Cr4 Cr
Net cash flow-0.41 Cr3 Cr-1 Cr8 Cr20 Cr-0.83 Cr156 Cr30 Cr
Free cash flow (OCF − Capex)-7 Cr6 Cr-77 Cr-9 Cr-31 Cr-155 Cr-76 Cr-36 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %30.6%24.4%27.2%18.7%19.2%9.8%16.7%28.0%
ROE %28.3%24.6%32.3%13.8%14.0%6.3%12.0%20.8%
Debtor days1168612911513610510599
Inventory days93139126145125130115142
Days payable16413617615315011210094
Cash conversion cycle458879107112123120146
OCF / EBITDA %35.3%66.0%33.9%-8.2%53.4%97.4%51.0%60.8%
OCF / EBITDA % (3 years)——42.3%20.1%27.3%51.1%64.0%63.7%
Debt / equity0.590.480.700.00160.00610.320.00620.02
Current ratio1.181.281.303.322.891.743.913.82
Net debt / EBITDA1.131.221.43-0.09-0.221.45-0.76-0.39